2016 and 2017 were difficult years for companies trying to win US Food and Drug Administration (FDA) approval for biosimilars of Amgen's blockbuster for treating side effects from chemotherapy. Last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results